Clinical Trial Update: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC [Phase 2]

View source ↗

Summary

A Phase II trial evaluating camrelizumab in combination with apatinib and eribulin for advanced breast cancer is ongoing; results are not yet reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN